It should be informative to evaluate the roles of ADCC, neutrophils, eosinophils and macrophages in this model, as done previously in other NMO models [26,16-29,33], as well as to test therapeutics targeting complement [37,38], NMO-IgG pathogenicity [35,36], NMO-IgG binding to AQP4 [34,49], and leukocyte-targeted drugs such as sivelestat [27] and cetirizine [29]. This evidence concerns the gene AQP4 and neuromyelitis optica.